ATP-生物荧光法在筛选卵巢癌化疗药物中的应用  

Application of ATP-bioluminescence Assay for Screening Chemotherapeutic Agents of Ovarian Cancer Chemotherapy

作　　者：邵长君[1] 田海梅[1] 傅军[1] 黄泓[1] 张伟[1] 

机构地区：[1]中国医学科学院肿瘤研究所肿瘤生物学检测中心,北京100021

出　　处：《标记免疫分析与临床》2003年第3期152-155,共4页Labeled Immunoassays and Clinical Medicine

摘　　要：为了探讨ATP -生物荧光法在临床体外化疗药敏试验中应用的可行性 ,本文以卵巢癌细胞株A2 780为实验模型 ,建立稳定和适宜的实验条件 ,并对卵巢癌临床化疗药物体外筛选进行了初步研究。结果表明该方法稳定性好 ,能检测出不同药物浓度对细胞作用的剂量 -效应关系 ,最小检出细胞数为 4 0个 ,实验变异系数小于 8.2 % (0 .2 % - 8.2 % ) ,预测准确率高 (90 .6 % )。ATP -生物荧光法稳定性、重复性和敏感性均较好 。To evaluate the feasibility of using ATP-bioluminescence assay for tumor chemosensitivity testing in vitro, we selected the A2780 cell line as a model and established the suitable assay condition. Screening chemotherapeutic agents of ovarian cancer in vitro were preliminarily researched. Using this assay, dose-response curve was detected in cell line treated with these agents. The result showed that the coefficients of variation for assay ranged from 0.2% to 8.2%, which means high reproducibility.It can measured ATP content of as few as forty cells. The thermal stability of the luciferin-luciferase system was high enough used in industry. The predictable accuracy rate is about 90.6%. This study demonstrated ATP-bioluminescence assay is a reliable, reproducible and sensitive method.It can provide a technical base for screening sensitive chemotherapeutic agents in clinic.

关 键 词：ATP-生物荧光法 筛选 卵巢癌 化疗药物 应用 

分 类 号：R737.31[医药卫生—肿瘤]